Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study

Por Church, Alison, Beerahee, Misba, Brooks, Jean, Mehta, Rashmi, Shah, Palvi
Publicado em 2014

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial

Por Singh, Dave, Worsley, Sally, Zhu, Chang-Qing, Hardaker, Liz, Church, Alison
Publicado no BMC Pulm Med (2015)

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study

Por Zheng, Jinping, Zhong, Nanshan, Newlands, Amy, Church, Alison, Goh, Aik H
Publicado no Int J Chron Obstruct Pulmon Dis (2015)

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies

Por Siler, Thomas M., Kerwin, Edward, Singletary, Karen, Brooks, Jean, Church, Alison
Publicado no COPD (2016)

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, ra...

Por Donohue, James F, Niewoehner, Dennis, Brooks, Jean, O’Dell, Dianne, Church, Alison
Publicado em 2014

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

Por Rheault, Tara, Khindri, Sanjeev, Vahdati-Bolouri, Mitra, Church, Alison, Fahy, William A.
Publicado no ERJ Open Res (2016)

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials

Por Riley, John H, Tabberer, Maggie, Richard, Nathalie, Donald, Alison, Church, Alison, Harris, Stephanie S
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

Por Siler, Thomas M, Donald, Alison C, O’Dell, Dianne, Church, Alison, Fahy, William A
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD

Por Feldman, Gregory, Maltais, François, Khindri, Sanjeev, Vahdati-Bolouri, Mitra, Church, Alison, Fahy, William A, Trivedi, Roopa
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

The effect of umeclidinium added to inhaled corticosteroid/long-acting β(2)-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study

Por Sousa, Ana R, Riley, John H, Church, Alison, Zhu, Chang-Qing, Punekar, Yogesh S, Fahy, William A
Publicado no NPJ Prim Care Respir Med (2016)

Mast cell desensitization inhibits calcium flux and aberrantly remodels actin

Por Ang, W.X. Gladys, Church, Alison M., Kulis, Mike, Choi, Hae Woong, Burks, A. Wesley, Abraham, Soman N.
Publicado no J Clin Invest (2016)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

Por Kerwin, Edward M, Kalberg, Chris J, Galkin, Dmitry V, Zhu, Chang-Qing, Church, Alison, Riley, John H, Fahy, William A
Publicado no Int J Chron Obstruct Pulmon Dis (2017)